A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection
Status:
Recruiting
Trial end date:
2024-07-25
Target enrollment:
Participant gender:
Summary
This study evaluates the addition of Tenofovir and Entecavir in the treatment of Hepatitis
B-related hepatocellular carcinoma after curative resection in adults. Half of participants
will receive Tenofovir disoproxil fumarate, while the other half will receive Entecavir.